These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 23727278)

  • 1. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
    Talele TT; McLaughlin ML
    J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation.
    Tripathi SK; Singh SK
    Mol Biosyst; 2014 Aug; 10(8):2189-201. PubMed ID: 24909777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
    Pasha FA; Neaz MM
    J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach.
    Tripathi SK; Soundarya RN; Singh P; Singh SK
    Chem Biol Drug Des; 2015 Feb; 85(2):107-18. PubMed ID: 24923208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
    Shen M; Zhou S; Li Y; Li D; Hou T
    Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
    Brylinski M
    J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extra precision docking, free energy calculation and molecular dynamics studies on glutamic acid derivatives as MurD inhibitors.
    Azam MA; Jupudi S
    Comput Biol Chem; 2017 Aug; 69():55-63. PubMed ID: 28575732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding microscopic binding of macrophage migration inhibitory factor with phenolic hydrazones by molecular docking, molecular dynamics simulations and free energy calculations.
    Xu L; Li Y; Li L; Zhou S; Hou T
    Mol Biosyst; 2012 Sep; 8(9):2260-73. PubMed ID: 22739754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
    Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
    J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
    Caballero J; Alzate-Morales JH; Vergara-Jaque A
    J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
    Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
    Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of multiple binding modes of the CDK2 inhibitors, anilinopyrazoles, using the automated docking programs GOLD, FlexX, and LigandFit: an evaluation of performance.
    Sato H; Shewchuk LM; Tang J
    J Chem Inf Model; 2006; 46(6):2552-62. PubMed ID: 17125195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
    Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
    J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
    Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL
    Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.